PRAX — Praxis Precision Medicines Share Price
0.000.00%
Last trade - 00:00- $725.88m
- $333.31m
- $8.55m
- 30
- 12
- 23
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.63 | ||
| Price to Tang. Book | 1.63 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 84.87 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.92% | ||
| Return on Equity | -70.98% | ||
| Operating Margin | -2340.29% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 2.45 | 8.55 | 1.34 | 11.89 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
Directors
- Dean Mitchell NEC (65)
- Marcio Souza PRE (42)
- Timothy Kelly CFO (48)
- Karl Hansen CTO
- Alex Nemiroff GCN (42)
- Bernard Ravina OTH (53)
- Megan Sniecinski OTH (40)
- Nicole Sweeny OTH (46)
- Alyssa Wyant OTH
- Jeffrey Chodakewitz IND (65)
- Merit Cudkowicz IND (58)
- Gregory Norden IND (63)
- Stefan Vitorovic IND (36)
- William Young IND (76)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 22nd, 2015
- Public Since
- October 16th, 2020
- No. of Shareholders
- 2
- No. of Employees
- 116
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 20,163,250
- Address
- 99 High Street, 30th Floor, BOSTON, 02110
- Web
- https://praxismedicines.com/
- Phone
- +1 6173008460
- Auditors
- Ernst & Young LLP
Upcoming Events for PRAX
Q1 2025 Praxis Precision Medicines Inc Earnings Release
Praxis Precision Medicines Inc Annual Shareholders Meeting
Q2 2025 Praxis Precision Medicines Inc Earnings Release
Similar to PRAX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Praxis Precision Medicines share price?
As of Today at 22:44 UTC, shares in Praxis Precision Medicines are trading at $36.00. This share price information is delayed by 15 minutes.
How has the Praxis Precision Medicines share price performed this year?
Shares in Praxis Precision Medicines last closed at $36.00 and the price had moved by -31.92% over the past 365 days. In terms of relative price strength the Praxis Precision Medicines share price has underperformed the S&P500 Index by -37.16% over the past year.
What are the analyst and broker recommendations for Praxis Precision Medicines?
The overall consensus recommendation for Praxis Precision Medicines is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Praxis Precision Medicines dividend yield?
Praxis Precision Medicines does not currently pay a dividend.
Does Praxis Precision Medicines pay a dividend?
Praxis Precision Medicines does not currently pay a dividend.
When does Praxis Precision Medicines next pay dividends?
Praxis Precision Medicines does not currently pay a dividend.
How do I buy Praxis Precision Medicines shares?
To buy shares in Praxis Precision Medicines you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Praxis Precision Medicines?
As of the previous close price of $36.00, shares in Praxis Precision Medicines had a market capitalisation of $725.88m.
Where are Praxis Precision Medicines shares listed?
Here are the trading details for Praxis Precision Medicines:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: PRAX
What kind of share is Praxis Precision Medicines?
Based on an overall assessment of its quality, value and momentum Praxis Precision Medicines is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Praxis Precision Medicines share price forecast for 2025?
The analyst consensus target price for shares in Praxis Precision Medicines is $82.20. That is 128.33% above the last closing price of $36.00.
Analysts covering Praxis Precision Medicines currently have a consensus Earnings Per Share (EPS) forecast of -$12.33 for the next financial year.
Find out moreWhat is the trend in the Praxis Precision Medicines share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Praxis Precision Medicines. Over the past six months, its share price has underperformed the S&P500 Index by -46.96%.
As of the last closing price of $36.00, shares in Praxis Precision Medicines were trading -40.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Praxis Precision Medicines PE Ratio?
The Praxis Precision Medicines PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $36.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Praxis Precision Medicines?
Praxis Precision Medicines' management team is headed by:
- Dean Mitchell - NEC
- Marcio Souza - PRE
- Timothy Kelly - CFO
- Karl Hansen - CTO
- Alex Nemiroff - GCN
- Bernard Ravina - OTH
- Megan Sniecinski - OTH
- Nicole Sweeny - OTH
- Alyssa Wyant - OTH
- Jeffrey Chodakewitz - IND
- Merit Cudkowicz - IND
- Gregory Norden - IND
- Stefan Vitorovic - IND
- William Young - IND